Table 3 Comparison of characteristics and examination findings with and without hepatotoxicity.
hepatotoxicity | no hepatotoxicity | p-value | |
|---|---|---|---|
Number of patients | 16 | 52 | |
Age | 75.0 (68.8–76.3) | 72.0 (68.0–76.0) | 0.519 |
Gender (male/female) | 11/5 | 41/11 | 0.502 |
Physique | |||
Height (cm) | 160 (153–166) | 164 (158–169) | 0.188 |
Body weight (kg) | 53.2 (49.2–57.9) | 62.0 (52.3–70.3) | 0.0765 |
Body mass index | 21.5 (19.4–24.3) | 22.4 (20.0–25.0) | 0.311 |
Body surface area (DuBois, m2) | 1.52 (1.45–1.67) | 1.67 (1.54–1.80) | 0.0484 |
Laboratory data | |||
Aspartate aminotransferase (IU/L) | 20.5 (16.5–31.5) | 21.0 (18.0–24.0) | 0.612 |
Alanine aminotransferase (IU/L) | 14.0 (11.0–29.0) | 14.0 (11.0–20.3) | 0.524 |
Alkaline phosphatase (IU/L) | 247 (211–280) | 240 (189–283) | 0.608 |
Total bilirubin (mg/dL) | 0.50 (0.40–0.62) | 0.50 (0.40–0.62) | 1.00 |
γ-glutamyl transpeptidase (IU/L) | 28.5 (21.5–63.8) | 28.0 (20.0–48.0) | 0.573 |
Creatinine (mg/dL) | 0.80 (0.68–0.90) | 0.83 (0.70–0.92) | 0.385 |
Krebs von den Lungen-6 (U/mL) | 920 (694–1356) | 1080 (766–1592) | 0.800 |
Surfactant protein D (ng/dL) | 262 (167–440) | 309 (188–400) | 0.691 |
Pulmonary function test | |||
forced vital capacity (L) | 1.75 (1.37–2.42) | 1.96 (1.65–2.34) | 0.457 |
%forced vital capacity (%) | 64.0 (55.0–71.7) | 60.9 (48.9–72.7) | 0.822 |
%DLCO (%) | 51.4 (36.1–60.1) | 50.4 (42.2–65.6) | 0.464 |
Six-minute walk test | |||
lowest SpO2 (%) | 81.5 (77.5–87.0) | 82.0 (76.0–87.0) | 0.922 |
walking distance (meter) | 378 (281–450) | 430 (355–480) | 0.299 |
Concomitant therapy | |||
Prednisolone (%) | 3 (18.8%) | 8 (15.4%) | 0.712 |
Cyclosporine (%) | 0 | 2 (3.8%) | 1.00 |
Cyclophosphamide (%) | 0 | 2 (3.8%) | 1.00 |
Tacrolimus (%) | 1 (6.2%) | 4 (7.7%) | 1.00 |
Pirfenidone (%) | 1 (6.2%) | 1 (1.9%) | 0.418 |
